176 related articles for article (PubMed ID: 22008114)
1. [The utilization and limitation of CD133 epitopes in lung cancer stem cells research].
Chen Y; Zhong H
Zhongguo Fei Ai Za Zhi; 2011 Oct; 14(10):825-9. PubMed ID: 22008114
[TBL] [Abstract][Full Text] [Related]
2. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells.
Chen YC; Hsu HS; Chen YW; Tsai TH; How CK; Wang CY; Hung SC; Chang YL; Tsai ML; Lee YY; Ku HH; Chiou SH
PLoS One; 2008 Jul; 3(7):e2637. PubMed ID: 18612434
[TBL] [Abstract][Full Text] [Related]
3. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.
Bidlingmaier S; Zhu X; Liu B
J Mol Med (Berl); 2008 Sep; 86(9):1025-32. PubMed ID: 18535813
[TBL] [Abstract][Full Text] [Related]
4. CD133: a cancer stem cells marker, is used in colorectal cancers.
Ren F; Sheng WQ; Du X
World J Gastroenterol; 2013 May; 19(17):2603-11. PubMed ID: 23674867
[TBL] [Abstract][Full Text] [Related]
5. Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells.
Meng X; Li M; Wang X; Wang Y; Ma D
Cancer Sci; 2009 Jun; 100(6):1040-6. PubMed ID: 19385971
[TBL] [Abstract][Full Text] [Related]
6. How powerful is CD133 as a cancer stem cell marker in brain tumors?
Cheng JX; Liu BL; Zhang X
Cancer Treat Rev; 2009 Aug; 35(5):403-8. PubMed ID: 19369008
[TBL] [Abstract][Full Text] [Related]
7. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
Hsu HS; Huang PI; Chang YL; Tzao C; Chen YW; Shih HC; Hung SC; Chen YC; Tseng LM; Chiou SH
Cancer; 2011 Jul; 117(13):2970-85. PubMed ID: 21225866
[TBL] [Abstract][Full Text] [Related]
8. Clinical and biological significance of stem-like CD133(+)CXCR4(+) cells in esophageal squamous cell carcinoma.
Lu C; Xu F; Gu J; Yuan Y; Zhao G; Yu X; Ge D
J Thorac Cardiovasc Surg; 2015 Aug; 150(2):386-95. PubMed ID: 26092504
[TBL] [Abstract][Full Text] [Related]
9. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy.
Liu J; Mao Z; Huang J; Xie S; Liu T; Mao Z
Biochem Biophys Res Commun; 2014 Feb; 444(4):670-5. PubMed ID: 24502949
[TBL] [Abstract][Full Text] [Related]
10. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.
Salnikov AV; Gladkich J; Moldenhauer G; Volm M; Mattern J; Herr I
Int J Cancer; 2010 Feb; 126(4):950-8. PubMed ID: 19676044
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of stem cell marker CD133 expression in colorectal cancer.
Wang BB; Li ZJ; Zhang FF; Hou HT; Yu JK; Li F
Histol Histopathol; 2016 Mar; 31(3):299-306. PubMed ID: 26442717
[TBL] [Abstract][Full Text] [Related]
12. Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and β-catenin, in primary lung adenocarcinoma--their prognostic significance.
Okudela K; Woo T; Mitsui H; Tajiri M; Masuda M; Ohashi K
Pathol Int; 2012 Dec; 62(12):792-801. PubMed ID: 23252868
[TBL] [Abstract][Full Text] [Related]
13. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K
Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031
[TBL] [Abstract][Full Text] [Related]
14. CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer.
Cui F; Wang J; Chen D; Chen YJ
Oncol Rep; 2011 Mar; 25(3):701-8. PubMed ID: 21174061
[TBL] [Abstract][Full Text] [Related]
15. [Investigation of CD133 as putative marker of tumor-initiating cell in laryngeal carcinoma].
Wei XD; Zhou L; Cheng L; Tian J
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Sep; 42(9):692-6. PubMed ID: 18051573
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer.
Alamgeer M; Ganju V; Szczepny A; Russell PA; Prodanovic Z; Kumar B; Wainer Z; Brown T; Schneider-Kolsky M; Conron M; Wright G; Watkins DN
Thorax; 2013 Dec; 68(12):1095-104. PubMed ID: 23878161
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem-like phenotype.
Srivastava VK; Nalbantoglu J
Cytometry A; 2008 Oct; 73(10):940-8. PubMed ID: 18773455
[TBL] [Abstract][Full Text] [Related]
18. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
19. Detection of cancer stem cell markers in sarcomas.
Veselska R; Skoda J; Neradil J
Klin Onkol; 2012; 25 Suppl 2():2S16-20. PubMed ID: 23581011
[TBL] [Abstract][Full Text] [Related]
20. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis.
Bi Y; Meng Y; Wu H; Cui Q; Luo Y; Xue X
J Surg Oncol; 2016 Feb; 113(2):144-51. PubMed ID: 26799258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
